U.S. regulators have approved an Alzheimer’s drug from Biogen that has shared the scientific community, marking a significant milestone for the disease’s sufferers and their families.
Aducanumab is intended for patients with mild to moderate Alzheimer’s disease. Biogen states that it reduces the progression of the disease by breaking the clumps of amyloid plaques that form in the brain.
The treatment has been surrounded by controversy for years, and many scientists have opposed its approval, saying it doesn’t work.
The U.S. Food and Drug Administration’s decision announced Monday is monumental since no new drugs have been approved for the disease in years, and very few treatments exist. Nearly 6 million people in the United States suffer from Alzheimer’s.
“We are well aware of the attention surrounding this approval,” said Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research, adding that “patients with Alzheimer’s have an important and critical new treatment to help them. fight against this disease ”.
Trading in Biogen shares was halted prior to the decision.
More to follow